These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1377314)

  • 1. Anticoagulation policy during use of aprotinin in cardiopulmonary bypass.
    van Oeveren W; van Oeveren B; Wildevuur CR
    J Thorac Cardiovasc Surg; 1992 Jul; 104(1):210-1. PubMed ID: 1377314
    [No Abstract]   [Full Text] [Related]  

  • 2. Guidelines for monitoring heparin by the activated clotting time when aprotinin is used during cardiopulmonary bypass.
    Hunt BJ; Segal HC; Yacoub M
    J Thorac Cardiovasc Surg; 1992 Jul; 104(1):211-2. PubMed ID: 1377315
    [No Abstract]   [Full Text] [Related]  

  • 3. Increased anticoagulation during cardiopulmonary bypass by aprotinin.
    de Smet AA; Joen MC; van Oeveren W; Roozendaal KJ; Harder MP; Eijsman L; Wildevuur CR
    J Thorac Cardiovasc Surg; 1990 Oct; 100(4):520-7. PubMed ID: 1699088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of aprotinin on activated clotting time, whole blood and plasma heparin measurements.
    Despotis GJ; Joist JH; Joiner-Maier D; Alsoufiev AL; Triantafillou AN; Goodnough LT; Santoro SA; Lappas DG
    Ann Thorac Surg; 1995 Jan; 59(1):106-11. PubMed ID: 7529483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased anticoagulation during cardiopulmonary bypass by aprotinin.
    Levy JH; Salmenpera MT
    J Thorac Cardiovasc Surg; 1991 Nov; 102(5):802. PubMed ID: 1719304
    [No Abstract]   [Full Text] [Related]  

  • 6. Alternative perioperative anticoagulation monitoring during cardiopulmonary bypass in aprotinin-treated patients.
    Huyzen RJ; Harder MP; Huet RC; Boonstra PW; Brenken U; van Oeveren W
    J Cardiothorac Vasc Anesth; 1994 Apr; 8(2):153-6. PubMed ID: 7515704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coagulation and fibrinolysis system in aortic surgery under deep hypothermic circulatory arrest with aprotinin: the importance of adequate heparinization.
    Okita Y; Takamoto S; Ando M; Morota T; Yamaki F; Matsukawa R; Kawashima Y
    Circulation; 1997 Nov; 96(9 Suppl):II-376-81. PubMed ID: 9386127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment.
    Esposito RA; Culliford AT; Colvin SB; Thomas SJ; Lackner H; Spencer FC
    J Thorac Cardiovasc Surg; 1983 Mar; 85(3):346-53. PubMed ID: 6827843
    [No Abstract]   [Full Text] [Related]  

  • 9. Aprotinin does not prolong the Sonoclot aprotinin-insensitive activated clotting time.
    Dong Y; Nuttall GA; Oliver WC; Agarwal S; Ereth MH
    J Clin Anesth; 2007 Sep; 19(6):424-8. PubMed ID: 17967670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of heparin-induced anticoagulation with kaolin-activated clotting time in cardiac surgical patients treated with aprotinin.
    Wang JS; Lin CY; Hung WT; Karp RB
    Anesthesiology; 1992 Dec; 77(6):1080-4. PubMed ID: 1281624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro effects of aprotinin on activated clotting time measured with different activators.
    Wang JS; Lin CY; Hung WT; Thisted RA; Karp RB
    J Thorac Cardiovasc Surg; 1992 Oct; 104(4):1135-40. PubMed ID: 1383640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extrinsic pathway--associated activated clotting time for anticoagulation monitoring during cardiopulmonary bypass.
    Gu YJ; Huyzen RJ; van Oeveren W
    Anesth Analg; 1996 Aug; 83(2):433. PubMed ID: 8694335
    [No Abstract]   [Full Text] [Related]  

  • 13. Heparin-coated devices and high-dose aprotinin optimally inhibit contact system activation in an in vitro cardiopulmonary bypass model.
    Wendel HP; Heller W; Gallimore MJ
    Immunopharmacology; 1996 May; 32(1-3):128-30. PubMed ID: 8796289
    [No Abstract]   [Full Text] [Related]  

  • 14. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of aprotinin on heparinized whole blood activated clotting time and whole blood prothrombin time].
    Wen Z; Zhu F; He X; Xiong S; He S
    Hunan Yi Ke Da Xue Xue Bao; 1997; 22(4):304-6. PubMed ID: 9868081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kaolin-based activated coagulation time measured by sonoclot in patients undergoing cardiopulmonary bypass.
    Ganter MT; Monn A; Tavakoli R; Klaghofer R; Zollinger A; Hofer CK
    J Cardiothorac Vasc Anesth; 2007 Aug; 21(4):524-8. PubMed ID: 17678778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of low doses of aprotinin on clotting times activated with celite and kaolin.
    Farooqi N; De Hert S; Vlaeminck R; De Bakker A; Govaerts E; Vermeyen K
    Acta Anaesthesiol Belg; 1993; 44(3):87-92. PubMed ID: 7508668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The in vitro effects of aprotinin on twelve different ACT tests.
    Jones K; Nasrallah F; Darling E; Clay N; Searles B
    J Extra Corpor Technol; 2004 Mar; 36(1):51-7. PubMed ID: 15095841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Control of temporary anticoagulation in extracorporeal circulation using activated coagulation time].
    Kessler G; Grünes G
    Anaesthesist; 1984 Dec; 33(12):588-91. PubMed ID: 6528961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of different forms of aprotinin during cardiopulmonary bypass.
    De Bakker A; De Hert S; Vlaeminck R; Delrue G; Govaerts E; Vermeyen K
    Acta Anaesthesiol Belg; 1993; 44(2):45-51. PubMed ID: 7694437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.